The US-China Economic and Security Review Commission said in a February 14 study that nine registered clinical studies in China were similar to He Jiankui’s genetically edited infant trials and that more than 80 patients had been tested. ”Part of the reason for Chinese companies’ progress in biotechnology is that the Chinese authorities have adopted more relaxed regulations and a more vague attitude toward the controversial topic of genetic editing,” the report wrote. check here The independent report was commissioned by the US-China Economic and Security Review Commission to commission two US research companies, Gryphon Scientific and Rhodium Group.

As we all know, China’s genetic editing baby research in 2018 is the adoption of CRISPR technology, but the global anger caused by the test “seriously violated academic ethics and academic norms.” On November 26, 2018, the Chinese party newspaper People’s Daily reported that “the world’s first genetically edited baby with immune AIDS was born in China.” At the same time, Chinese scientist He Jiankui, who conducted the experiment, announced through a series of overseas media and social media that a pair of “healthy” genetically edited babies “Lulu” and “Nana” were born. When the news came out, it was shocking. Many issues such as ethics and scientific reliability involved in the experiment immediately caused doubts and condemnations from the scientific community at home and abroad. 122 Chinese scientists published an open letter warning the huge risk of the CRISPR gene editing technology used by the He Jiankui test team, and criticized the authorities for “biomedical ethics review is in vain.” At least eight other trials similar to He Jiankui in China have not published results.check here

In fact, He Jiankui’s experiment is only one example of China’s CRISPR test. According to the US-China Economic and Security Review Commission, according to the results of public channel statistics, as of the end of February 2018, there were 9 registered clinical studies in China on” the use of CRISPR cell editing methods to treat cancer and HIV”, there were more than 80 patients accepted the trial.

The earliest CRISPR trial in China began in October 2016, check here and Sichuan University first used CRISPR to treat human disease (for acute lung cancer) in clinical trials. As the research is still in progress, it is not known whether the test results are successful or failed. Because gene-targeting research for disease treatment is still in its infancy compared to other technologies using drugs or antibodies, the same is true for CRISPR gene editing, which is rarely used in foreign countries. In contrast, there is only one such trial in the United States.

In addition, foreign laws prohibit human trials of such technologies. Strictly speaking, because Chinese officials have not issued regulations prohibiting manipulation or control of human genetic editing, such tests can still be conducted in China. In contrast, US regulators have adopted a more cautious approach to the approval of such tests, and have also imposed stringent safety requirements, and so far the United States has not approved and started pilot projects. The United Kingdom, Western European countries, Canada, Australia, and South Korea also have clear laws prohibiting such research.